DiaMedica Therapeutics Inc. Retained Earnings
DiaMedica Therapeutics Inc. (DMAC) had Retained Earnings of -$192.95 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$192.95M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$182.81M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$172.77M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$164.03M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$192.95M 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$182.81M 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$172.77M 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$164.03M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$155.41M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$147.71M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$140.00M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$132.10M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$125.83M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$120.71M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$115.56M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$110.40M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$105.93M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$101.45M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$96.18M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$92.43M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$89.37M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$86.01M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$82.50M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$79.25M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$75.81M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$72.53M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$68.91M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$64.71M 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$61.52M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$59.04M 10-Q · filed 2020-05-13 |
| 2019-12-31 | -$56.62M 10-K · filed 2021-03-10 |
| 2019-09-30 | -$54.14M 10-Q · filed 2019-11-13 |
| 2019-06-30 | -$51.69M 10-Q · filed 2019-08-13 |
| 2019-03-31 | -$49.22M 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$45.97M 10-K · filed 2020-03-23 |
| 2017-12-31 | -$40.23M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |